{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:29:34Z","timestamp":1774621774055,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["FISR2019_00374 MeDyCa, B84G19000200008 (CD)"],"award-info":[{"award-number":["FISR2019_00374 MeDyCa, B84G19000200008 (CD)"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Epi-MET D.M. 31.12.2021, D.D. 18.03.2022 no. 34"],"award-info":[{"award-number":["Epi-MET D.M. 31.12.2021, D.D. 18.03.2022 no. 34"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministero delle Imprese e del Made in Italy","award":["EPI-GA F\/350261\/01-04\/X60, B69I23003210007 (CD)"],"award-info":[{"award-number":["EPI-GA F\/350261\/01-04\/X60, B69I23003210007 (CD)"]}]},{"name":"Ministero delle Imprese e del Made in Italy","award":["NABUCCO F\/260018\/03\/X51, B29J24001270005 (LA)"],"award-info":[{"award-number":["NABUCCO F\/260018\/03\/X51, B29J24001270005 (LA)"]}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca,","doi-asserted-by":"crossref","award":["PRIN-2022-PNRR-SOLAR-P2022NFCPM, B53D23025100001 (CD)"],"award-info":[{"award-number":["PRIN-2022-PNRR-SOLAR-P2022NFCPM, B53D23025100001 (CD)"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"crossref"}]},{"name":",","award":["Project F\/310034\/03\/X56, B29J24000550005 (LA)"],"award-info":[{"award-number":["Project F\/310034\/03\/X56, B29J24000550005 (LA)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01784-9","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T15:53:03Z","timestamp":1771775583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["UVI5008: the first reversible, non-covalent Bruton\u2019s tyrosine kinase epi-inhibitor for B-cell malignancies"],"prefix":"10.1186","volume":"19","author":[{"given":"Carmela","family":"Dell\u2019Aversana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sgueglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. L.","family":"Megchelenbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Carafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Campanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Frenquelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bordini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. B.","family":"Petrizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Chiurazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. P.","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"de Lera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Altucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"1784_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147516","author":"S Mehra","year":"2024","unstructured":"Mehra S, Nicholls M, Taylor J. The evolving role of Bruton\u2019s tyrosine kinase inhibitors in B cell lymphomas. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25147516.","journal-title":"Int J Mol Sci"},{"key":"1784_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.650414","volume":"9","author":"FM Uckun","year":"2021","unstructured":"Uckun FM, Venkatachalam T. Targeting solid tumors with BTK inhibitors. Front Cell Dev Biol. 2021;9:650414.","journal-title":"Front Cell Dev Biol"},{"key":"1784_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/bph.17344","author":"S Chen","year":"2024","unstructured":"Chen S, Liu Y, Zhang Y, Guo X, Bai T, He K, et al. Bruton\u2019s tyrosine kinase inhibition suppresses pathological retinal angiogenesis. Br J Pharmacol. 2024. https:\/\/doi.org\/10.1111\/bph.17344.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"1784_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/10428194.2024.2342560","volume":"65","author":"C von Roemeling","year":"2024","unstructured":"von Roemeling C, Ferreri AJM, Soussain C, Tun HW, Grommes C. Targets and treatments in primary CNS lymphoma. Leuk Lymphoma. 2024;65(8):1055\u201367.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1784_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.2021013326","volume":"139","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed\/refractory mantle cell lymphoma. Blood. 2022;139(5):666\u201377.","journal-title":"Blood"},{"key":"1784_CR6","unstructured":"Mukkamalla SKR, Taneja A, Malipeddi D, Master SR. Chronic Lymphocytic Leukemia. StatPearls. Treasure Island (FL).2025."},{"issue":"7","key":"1784_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40266-017-0468-4","volume":"34","author":"A Aw","year":"2017","unstructured":"Aw A, Brown JR. Current status of Bruton\u2019s tyrosine kinase inhibitor development and use in B-cell malignancies. Drugs Aging. 2017;34(7):509\u201327.","journal-title":"Drugs Aging"},{"issue":"10453","key":"1784_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","volume":"404","author":"N Jain","year":"2024","unstructured":"Jain N, Wierda WG, O\u2019Brien S. Chronic lymphocytic leukaemia. Lancet. 2024;404(10453):694\u2013706.","journal-title":"Lancet"},{"key":"1784_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589","volume":"7","author":"JA Burger","year":"2016","unstructured":"Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589.","journal-title":"Nat Commun"},{"key":"1784_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.790004","volume":"11","author":"M Kwok","year":"2021","unstructured":"Kwok M, Wu CJ. Clonal evolution of high-risk chronic lymphocytic leukemia: a contemporary perspective. Front Oncol. 2021;11:790004.","journal-title":"Front Oncol"},{"issue":"1","key":"1784_CR11","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2025.053","volume":"17","author":"S Molica","year":"2025","unstructured":"Molica S, Allsup D. Bruton\u2019s tyrosine kinase (BTK) mutations in chronic lymphocytic leukemia (CLL): a clinical view. Mediterr J Hematol Infect Dis. 2025;17(1):e2025053.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1784_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2567834","author":"S Ibrahim","year":"2025","unstructured":"Ibrahim S, Pham N, Sahni A, Sekeres S, Cool A, Taylor J, et al. Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2025. https:\/\/doi.org\/10.1080\/14796694.2025.2567834.","journal-title":"Future Oncol"},{"issue":"9","key":"1784_CR13","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","volume":"39","author":"P Blombery","year":"2025","unstructured":"Blombery P, Chatzikonstantinou T, Gerousi M, Rosenquist R, Gaidano G, Pospisilova S, et al. Resistance to targeted therapies in chronic lymphocytic leukemia: current status and perspectives for clinical and diagnostic practice. Leukemia. 2025;39(9):2049\u201360.","journal-title":"Leukemia"},{"issue":"10","key":"1784_CR14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1784_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s10238-023-01268-x","volume":"24","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang H, Zhang Y, Wang X. Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment. Clin Exp Med. 2024;24(1):54.","journal-title":"Clin Exp Med"},{"issue":"10","key":"1784_CR16","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/2159-8290.CD-24-0296","volume":"14","author":"M Esteller","year":"2024","unstructured":"Esteller M, Dawson MA, Kadoch C, Rassool FV, Jones PA, Baylin SB. The epigenetic hallmarks of cancer. Cancer Discov. 2024;14(10):1783\u2013809.","journal-title":"Cancer Discov"},{"key":"1784_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070824","author":"I Maietta","year":"2022","unstructured":"Maietta I, Martinez-Perez A, Alvarez R, De Lera AR, Gonzalez-Fernandez A, Simon-Vazquez R. Synergistic antitumoral effect of epigenetic inhibitors and gemcitabine in pancreatic cancer cells. Pharmaceuticals (Basel). 2022. https:\/\/doi.org\/10.3390\/ph15070824.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1784_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/md19010015","author":"M Conte","year":"2020","unstructured":"Conte M, Fontana E, Nebbioso A, Altucci L. Marine-derived secondary metabolites as promising epigenetic bio-compounds for anticancer therapy. Mar Drugs. 2020. https:\/\/doi.org\/10.3390\/md19010015.","journal-title":"Mar Drugs"},{"key":"1784_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1072651","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wang G, Li Y, Lei D, Xiang J, Ouyang L, et al. Recent progress in DNA methyltransferase inhibitors as anticancer agents. Front Pharmacol. 2022;13:1072651.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1784_CR20","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/1535-7163.MCT-11-0525","volume":"10","author":"A Nebbioso","year":"2011","unstructured":"Nebbioso A, Pereira R, Khanwalkar H, Matarese F, Garcia-Rodriguez J, Miceli M, et al. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. Mol Cancer Ther. 2011;10(12):2394\u2013404.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1784_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","volume":"126","author":"F McClanahan","year":"2015","unstructured":"McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood. 2015;126(2):203\u201311.","journal-title":"Blood"},{"key":"1784_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203434","author":"A Bravo-Gonzalez","year":"2024","unstructured":"Bravo-Gonzalez A, Alasfour M, Soong D, Noy J, Pongas G. Advances in targeted therapy: addressing resistance to BTK inhibition in B-cell lymphoid malignancies. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16203434.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"1784_CR23","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1039\/D0SC06122K","volume":"12","author":"AT Voice","year":"2021","unstructured":"Voice AT, Tresadern G, Twidale RM, van Vlijmen H, Mulholland AJ. Mechanism of covalent binding of ibrutinib to Bruton\u2019s tyrosine kinase revealed by QM\/MM calculations. Chem Sci. 2021;12(15):5511\u20136.","journal-title":"Chem Sci"},{"issue":"10","key":"1784_CR24","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.1021\/acs.jmedchem.3c01825","volume":"67","author":"L Hillebrand","year":"2024","unstructured":"Hillebrand L, Liang XJ, Serafim RAM, Gehringer M. Emerging and re-emerging warheads for targeted covalent inhibitors: an update. J Med Chem. 2024;67(10):7668\u2013758.","journal-title":"J Med Chem"},{"key":"1784_CR25","doi-asserted-by":"crossref","unstructured":"Zheng L, Li Y, Wu D, Xiao H, Zheng S, Wang G, Sun Q. Development of covalent inhibitors: Principle, design, and application in cancer. MedComm\u2013Oncology. 2023.","DOI":"10.1002\/mog2.56"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01784-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01784-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01784-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:36:48Z","timestamp":1774618608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01784-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1784"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01784-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"C. Dell\u2019Aversana and L. Altucci are inventors for the patent no. 102025000013429 entitled: \u201cNUOVO INIBITORE DELLA TIROSIN-CHINASI DI BRUTON, SUOI DERIVATI ED USI FARMACEUTICI\"","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"19"}}